price up icon1.70%   +6.60
after-market  After Hours:  410.00  15.53   +3.94%
Argen X SE ADR stock is currently priced at $394.47, with a 24-hour trading volume of 558.62K. It has seen a +1.70% increased in the last 24 hours and a +10.60% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $385.1 pivot point. If it approaches the $399.6 resistance level, significant changes may occur.
Previous Close:
24h Volume:
Market Cap:
Net Income/Loss:
P/E Ratio:
Net Cash Flow:
1W Performance:
1M Performance:
6M Performance:
1Y Performance:
1D Range:
52W Range:

Argen X SE ADR Stock (ARGX) Company Profile

Argen X SE ADR
Willemstraat 5, Breda
Next Earnings Date
Latest SEC Filings
ARGX's Discussions on Twitter

Argen X SE ADR Stock (ARGX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-20-23 Downgrade Deutsche Bank Buy → Hold
Dec-20-23 Downgrade William Blair Outperform → Mkt Perform
Jul-31-23 Initiated Scotiabank Sector Perform
Jul-24-23 Downgrade UBS Buy → Neutral
Jul-17-23 Resumed Evercore ISI Outperform
Jun-15-23 Initiated Societe Generale Sell
May-31-23 Initiated UBS Buy
Apr-25-23 Initiated Citigroup Buy
Mar-14-23 Upgrade Robert W. Baird Neutral → Outperform
Dec-07-22 Initiated William Blair Outperform
Oct-12-22 Initiated Oppenheimer Perform
Jul-29-22 Downgrade Robert W. Baird Outperform → Neutral
Jun-28-22 Resumed Stifel Buy
May-03-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-08-21 Initiated Wells Fargo Overweight
Nov-29-21 Upgrade Piper Sandler Neutral → Overweight
Oct-29-21 Upgrade Guggenheim Neutral → Buy
Oct-28-21 Upgrade Raymond James Outperform → Strong Buy
Oct-07-21 Initiated Jefferies Buy
Sep-23-21 Upgrade Redburn Neutral → Buy
Sep-07-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-23-21 Initiated Deutsche Bank Hold
Jul-19-21 Resumed Wolfe Research Outperform
Jun-18-21 Initiated UBS Buy
Jun-04-21 Resumed Robert W. Baird Outperform
May-10-21 Upgrade H.C. Wainwright Neutral → Buy
Apr-23-21 Initiated Redburn Neutral
Mar-05-21 Reiterated H.C. Wainwright Neutral
Feb-02-21 Downgrade Piper Sandler Overweight → Neutral
Jan-04-21 Downgrade Guggenheim Buy → Neutral
Aug-25-20 Initiated Raymond James Outperform
Aug-19-20 Downgrade Evercore ISI Outperform → In-line
Jul-29-20 Initiated H.C. Wainwright Neutral
Feb-10-20 Initiated BofA/Merrill Buy
Nov-05-19 Initiated Credit Suisse Neutral
Oct-31-19 Upgrade William Blair Mkt Perform → Outperform
Oct-22-19 Initiated JP Morgan Overweight
Sep-27-19 Initiated Wells Fargo Market Perform
Sep-16-19 Resumed Cowen Outperform
Jun-28-19 Initiated Robert W. Baird Outperform
Jan-18-19 Resumed SunTrust Buy
Jan-04-19 Initiated Morgan Stanley Overweight
Dec-17-18 Initiated Goldman Buy
Dec-14-18 Initiated Wolfe Research Outperform
Jun-29-18 Initiated Nomura Buy
Apr-09-18 Initiated SunTrust Buy
Jan-29-18 Reiterated JMP Securities Mkt Outperform
View All

Argen X SE ADR Stock (ARGX) Financials Data

Argen X SE ADR (ARGX) Revenue 2024

ARGX reported a revenue (TTM) of $1.41 billion for the quarter ending March 31, 2024, a +132.19% rise year-over-year.

Argen X SE ADR (ARGX) Net Income 2024

ARGX net income (TTM) was -$327.78 million for the quarter ending March 31, 2024, a +35.89% increase year-over-year.

Argen X SE ADR (ARGX) Cash Flow 2024

ARGX recorded a free cash flow (TTM) of -$910.55 million for the quarter ending June 30, 2023.

Argen X SE ADR (ARGX) Earnings per Share 2024

ARGX earnings per share (TTM) was -$5.67 for the quarter ending March 31, 2024, a +38.90% growth year-over-year.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
price up icon 5.27%
price down icon 1.44%
price up icon 0.58%
price up icon 0.37%
price down icon 1.10%
Cap:     |  Volume (24h):